The older person with co morbidities. Eugene Hughes General Practitioner Isle of Wight
|
|
- Grant Stewart
- 5 years ago
- Views:
Transcription
1 The older person with co morbidities Eugene Hughes General Practitioner Isle of Wight
2 Eugene Hughes Age 60 BMI 26.5 BP 125/70 Alcohol intake moderate (?) TC 5.6 Regular exercise Non smoker Stress free
3 Eugene Hughes Mother has type 2 diabetes Father died of MI age 51 Grandmother had type 2 diabetes, died age 95 Uncle has type 2 diabetes HbA1c = 50 mmol/mol on 2 occasions, no symptoms
4 What next for me? Lifestyle change? VLC diet? Commence metformin? Commence statin? Commence aspirin?
5 Priorities? Glucose, lipids, BP BP, lipids, glucose Lipids, glucose, BP Glucose, BP, lipids
6 HbA1c target? < mmol/mol < mmol/mol < mmol/mol
7 Would it be different if I was 70? 80? 90?
8 Would it be different if I was Frail, whatever that means? Lacking mental capacity? Recently diagnosed with prostate cancer?
9 Contents What evidence exists for the management of blood pressure, blood glucose and lipids in the elderly population? Can we define frailty? What about end of life care in people with diabetes?
10 Why is it important? Globally, diabetes is being diagnosed in epidemic proportions and whilst the estimated diabetes prevalence for 2013 is 382 million it is expected to affect 592 million people by By 2050, the proportion of older persons (over age 60 as defined by the UN) will have risen from 15% today to 25%. These changes present significant challenges to welfare, pension, and healthcare systems
11 IDF guideline on older people with diabetes It is increasingly important that modern recommendations for managing diabetes are more closely aligned with additional individual characteristics such as; functional status, presence of frailty and dependency, comorbidity profiles, life expectancy.
12 Co morbidity Hypertension Renal disease CV disease Depression Arthritis Sexual dysfunction Cancer
13 Polypharmacy Statins Fibrates NSAIDs Warfarin / NOACs Aspirin Clopidogrel PPIs Antidepressants Antipsychotics Antihypertensives Diuretics Osteoporosis OTC Gabapentin
14 POLYPILL Atorvastatin Ramipril Metformin A2RA Gliptin Ezetimide Diuretic Dispersible aspirin Omeprazole Nicotinic acid
15 Case study 1 Brian, aged 81, T2D Metformin 1000mg bd Gliclazide 80mg bd Lisinopril 20mg od Bendroflumethiazide 2.5mg od Simvastatin 40mg od Paracetamol PRN BP 126/76 TC 4.2 mmol/mol HbA1c 51mmol/mol (6.8%) Widow, lives alone Poor mobility Son does shopping C/o tiredness
16 Brian, 81 Ask Brian what he wants and discuss appropriate goals Ask him to discuss it with his son Is he depressed??stop gliclazide ( hypo risk)?stop bendro ( BP is low) Does he need statin, Lisinopril, metformin?
17 Mabel, 84, in a nursing home CVA Can t speak Bedbound PEG feed BP 110/70 TC 4.2 mmol /L HbA1c 66 mmol/mol (8.2%) Aspirin disp 75mg od Simvastatin oral soln 40mg od Ramipril oral soln 5mg od Omeprazole disp 20mg od Metformin soln 500mg bd Co codamol eff 2 qds Glargine 40 units daily
18 Mabel Try to ascertain Mabel s wishes, along with her family and carers Stop Ramipril ( BP too low) Consider stopping statin, aspirin, insulin, omeprazole?change to soluble paracetamol
19 Guiding principles An holistic, individualized care plan is needed for each older person with diabetes. It is important to adopt a proactive risk identification and minimization approach that includes planning for key transitions in older people such as stopping driving, moving to aged care homes, or supported community care and end of life care. A focus on patient safety, avoiding hospital/emergency department admissions and institutionalization by recognizing the deterioration early and maintaining independence and quality of life to a dignified death.
20 Categories of older people with diabetes (IDF) Functionally independent living independently no impairment of ADL Functionally dependent frail dementia End of life care
21 Frailty definition low grip strength, less than 20% of normal low energy, self reported slowed walking speed, measured over 15 feet low physical activity unintentional weight loss Rockwood, Age and Ageing 2005; 34:
22 The Grim Reaper Walking speed 0.82 m/s
23 Medicines management in older people Medicines are associated with significant risks in older people such as falls, confusion and other cognitive changes, and admission to hospital Older people experience a disproportionate number of medicine related adverse events, even adjusting for age When new symptoms emerge: consider any new symptom as related to a medicine/s until proven otherwise.
24 Medicines management in older people Consider the medicine burden and reduce polypharmacy, the complexity of the dose regimen, and consider stopping medicines where possible and safe (deprescribing). Use the lowest effective dose, increase doses slowly, and monitor the effects including adverse effects, Anticipate difficulties adhering to the medicine regimen and consider whether alternative dose forms are needed (e.g. swallowing difficulties)
25 Quality use of medicines Consider factors that contribute to medicines related adverse outcomes; Polypharmacy Inappropriate prescribing Presence of renal / hepatic impairment Living alone Cognitive impairment Sensory deficits
26 CV risk assessment All people with diabetes aged 60+ years are considered at high cardiovascular risk and application of a risk equation is unnecessary. All people with diabetes aged 60 and over are at increased CVD risk and should be considered for CVD prevention measures. However since many interventions take a number of years to demonstrate benefit, their initiation may not be warranted in those with a limited life expectancy. The Framingham risk score has been validated for people up to 75 years but has been shown to be unreliable in older persons
27 Addressing CV risk Functionally independent Modifiable individual cardiovascular risk factors should be treated as for younger people with diabetes. Functionally dependent The emphasis should be on the identification and management of more easily modifiable risk factors End of life care Specific assessment of cardiovascular risk is usually unnecessary.
28 Glucose control general recommendations Glycaemic control targets should be individualized taking into account functional status, comorbidities, especially the presence of established CVD, history and risk of hypoglycaemia, and presence of microvascular complications. Discuss with the individual and principal caregiver care goals and medicine dose, regimen, and tablet burden before choosing glucose lowering agents. Use the start low and go slow principle in initiating and increasing medication and monitor response to each initiation or dose increase for up to a 3 month trial period. Consider discontinuing ineffective and unnecessary therapies.
29 Glucose control by category Functionally independent target HbA1c is % (53 59 mmol/mol) Functionally dependent target HbA1c of up to 8.5% (70 mmol/mol) may be appropriate End of life care Minimize hypoglycaemia and symptomatic hyperglycaemia Consider appropriate withdrawal of therapy, including insulin, in the terminal stages
30 Evidence base Whilst the evidence is increasing that blood pressure and lipid reduction also have specific benefits in older people above the age of 70 years, the evidence for tight glucose control is not available. Furthermore, recent studies are suggesting that a higher target glycated haemoglobin (HbA 1c ) range may be more appropriate and safer. Improved glycaemic control appears to have minimal effect on CVD in the medium term and can take up to 20 years to show a significant reduction in coronary artery disease outcomes. The ACCORD study reported that attempts at aggressive improvement in glycaemic control increased mortality The emphasis is on achieving glycaemic levels that prevent and minimize vascular complications of diabetes but also minimize the risk of hypoglycaemia.
31 Individual agents metformin Preferred first line agent in older people (REACH) registry showed overall lower 2 year mortality in people with atherothrombosis treated with metformin vs. without metformin egfr reduce dose at 45, stop at 30 GI side effects Care with dehydration states
32 Sulphonylureas Do not use glibenclamide! Gliclazide has lowest risk of hypoglycaemia Sulfonylureas are a good choice for older adults who eat consistently and are able to recognize and treat hypoglycaemia appropriately. (IDF) Consider alternatives in drivers and those living alone and egfr less than 45
33 Safe Drivers A concerned pensioner rang her 90 year old husband whilst he was driving. 'Albert, be careful, they've just said on the radio there's someone driving the wrong way on the M6' 'Im on the M6 now' he replied. 'But there's not just one going the wrong way there's hundreds of them!'
34 Glinides The glinides (repaglinide and nateglinide) are rapid acting insulin secretagogues with a shorter half life (60 90 minutes) compared with sulfonylureas. These medicines need to be taken just before meals and can be skipped if meals are skipped, thus avoiding hypoglycaemia in frail older people or those with dementia with irregular eating habits.
35 Glitazones (TZD) Weight gain / fluid retention Fractures Heart failure Bladder cancer risk largely disproved (JAMA. 2015;314: , , )
36 DPP4 inhibitors Safe in elderly Safe in impaired renal function (dose may need adjusting) Low risk of hypoglycaemia Weight neutral Recent studies demonstrated CV safety (TECOS)
37 GLP1 RA Limited data for use in older people Once weekly preparations available Expensive GI side effects common Weight loss may be disadvantage in older people ELIXA study (2015) showed CV safety (lixisenatide)
38 SGLT2 inhibitors Experience limited in elderly Increased risk of urinary and genital tract infections Less effective in renal insufficiency Hypovolaemia, postural hypotension, and weight loss may limit their use in some older people. DKA (recent FDA warning) Does EMPA REG change everything?
39 Insulin A recent analysis of pooled data from randomized studies has shown that the relative contribution of basal hyperglycaemia is lower and that of postprandial hyperglycaemia is greater in older compared with younger people at all HbA 1c levels In older people with diabetes, the type of insulin (basal, premixed, prandial) now provides flexibility to tailor treatment regimens to individual needs. Recent Cochrane review showed neither short acting or long acting preparations demonstrated superiority Prandial insulin, especially when used in a complex regimen strategy, may increase risk of errors in older people.
40 Blood pressure general The diagnosis of hypertension should be based on at least three different blood pressure measurements, taken on more than two separate visits. A diagnosis of hypertension is established by demonstrating a SBP 140 mmhg and/or a diastolic blood pressure (DBP) 90 mmhg on at least two occasions. Renal function and electrolytes should be monitored at the commencement of pharmacotherapy.
41 BP control by category Functionally independent These individuals should be managed to achieve a target blood pressure of less than 140/90 mmhg Functionally dependent atarget blood pressure of up to 150/90 mmhg may be appropriate Care with diuretics in the frail increased falls, inconvenient micturition End of life Unless the blood pressure readings are immediately life threatening, strict control of blood pressure may not be necessary, and withdrawal of blood pressure lowering therapy may be appropriate.
42 Evidence Treating hypertension reduces the risk of stroke and other adverse cardiovascular events. A 2011 meta analysis of randomized controlled trials in hypertensive people aged 75 and over concluded that treatment reduced cardiovascular morbidity and mortality and the incidence of heart failure, even though total mortality was not affected. Hypertensive people with diabetes are also at increased risk for diabetes specific complications including nephropathy and retinopathy. Results of the ACCORD blood pressure trial among people older than 65 years of age found no additional benefit of a target systolic pressure less than 120 mmhg compared with a target of 140 mmhg.
43 Individual agents ACE inhibitors should be considered the medication of choice in older people with diabetes. ARBs are a proven alternative and can be used if ACEi not tolerated. Beta blockers can be considered, especially in people with an elevated pulse rate. The main concern is the masking of hypoglycaemic symptoms. CCBs reduce cardiovascular events in people with diabetes and hypertension. However, they have been shown to be inferior to other agents in reducing some cardiovascular outcomes. Alpha blockers may be helpful in older people as add on therapy, especially in men with prostate enlargement.
44 Lipid control general Assessment of lipids is an integral part of cardiovascular risk assessment. A full lipid profile, including total cholesterol, LDL cholesterol, HDLcholesterol, and triglycerides should be assessed initially and then at clinically relevant intervals. All older people with diabetes are at high CVD risk and should be considered for treatment with a statin unless contraindicated or considered clinically inappropriate. Lower statin doses should be used and indications of side effects (especially muscular and hepatic) or possible drug interaction monitored.
45 Lipid control by category Functionally independent These individuals should be actively managed to reduce CVD risk. All treatment options generally apply to this category with statins as firstline therapy. Functionally dependent The principles are as for Category 1: Functionally Independent. Caregivers should be provided with sufficient knowledge and support to arrange the safe administration of lipid lowering therapy and monitor side effects. End of life care Lipid lowering therapy is not usually necessary, and withdrawal of therapy may be appropriate.
46 Evidence Lowering serum cholesterol by 1 mmol/l reduces risk of coronary heart disease mortality by 50% in people aged years while the risk reduction is 33% in those aged years and 15% in those aged years Although relative risk reduction decreases with age, the absolute effects of lower cholesterol on coronary heart disease reduction in older subjects are greater due to the higher prevalence of atheroma and CVD. However evidence for benefits of treatment in people aged over 80 years is limited and clinicians need to make decisions based on individualized management.
47 Statins Statins are most beneficial for preventing cardiovascular events in people who already have coronary heart disease and reduce vascular events and mortality In older adults, exposure to higher doses of statins or higher potency statins does not increase their effectiveness, but does increase the risk of adverse effects such as myopathy and cognitive impairment. The effect of statins on cognition are conflicting. In people with dementia, statins do not significantly affect cognitive decline, global function, behaviour or activities of daily living. However one study has reported that statin withdrawal was associated with improvements in cognitive function in people with Alzheimer s disease and rechallenge with statins was associated with a decline in cognition function
48 End of life care The main principles of diabetes care at the end of life include; Provision of a painless and symptom free death Tailoring blood glucose therapies Avoidance of metabolic complications such as DKA and hypoglycaemia Avoidance of dehydration Medications, including glucose lowering medications and insulin may need to be reduced or stopped as the patient with diabetes progresses through the end of life stages Changes in eating pattern, activity levels and renal function may need to be taken into consideration
49 Medications The dose of metformin, gliptins and SGLT2 inhibitors needs to be reviewed in the face of changing renal function. Sulphonylurea dose should be reviewed if dietary intake is reduced this may also be the case with GLP 1 analogues. Insulin doses may need to change with changes in renal function Hypoglycaemia risk will need to be considered with changes in eating patterns. Equipment for insulin delivery may need to be reassessed if physical capabilities alter.
50 Word of the week? Deprescribe
51 Thank you for listening!
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationDr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?
Dr Tahseen A. Chowdhury Royal London Hospital New Guidelines in Diabetes: NICE or Nasty? I have no conflicts of interest I do not undertake talks / advisory bodies / research for any pharma company Consultant
More informationVolume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)
Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) The purpose of this special edition of the PACE Bulletin is to summarize the
More informationManagement of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE
Management of DM in Older Adults: It s not all about sugar! Peggy Odegard, Pharm.D., BCPS, CDE Who needs treatment for DM? 87 year old, frail male with moderately severe dementia living in NH with persistent
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationMedication Reviews within Care Homes. Catherine Armstrong
Medication Reviews within Care Homes Catherine Armstrong What is a Medication Review? A structured, critical examination of a patient s medicines with the objective of reaching an agreement with the patient
More informationDiabetes in the Elderly 1, 2, 3
Diabetes in the Elderly 1, 2, 3 WF Mollentze Feb 2010 Diabetes in the elderly differs from diabetes in younger people Prevalence: o Diabetes increases with age affecting approximately 10% of people over
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationDiabetes in the UK: Update on Diabetes Treatment and Care. Why is diabetes increasing? Obesity Increased waist circumference.
Update on Diabetes Treatment and Care Tahseen A Chowdhury Consultant Diabetologist Royal London and Mile End Hospitals Diabetes prevalence (thousands) Diabetes in the UK: 1995-21 3 25 2 15 1 5 Type 1 Type
More informationCase study: Lean adult with no complications, newly diagnosed with type 2 diabetes
Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Authored by Clifford Bailey and James LaSalle on behalf of the Global Partnership for Effective Diabetes Management. The
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationFrailty and Type 2 Diabetes Guidelines for clinicians
H.G. WELLS PROJECT Frailty and Type 2 Diabetes Guidelines for clinicians Victoria Ruszala victoria.ruszala@nhs.net H.G. Wells Project team Dugal T, Partington E. Kernow CCG Diabetes and Frailty Guideline
More informationGuideline for antihyperglycaemic therapy in adults with type 2 diabetes
Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin
More informationDiabetic Management in the Frail Older Patient
Diabetic Management in the Frail Older Patient A S S O C P R O F. P A U L V A R G H E S E, D I R E C T O R O F G E R I A T R I C M E D I C I N E, P R I N C E S S A L E X A N D R A H O S P I T A L. Outline
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated November 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationOral Treatments for Type 2 Diabetes. Prescribing Support Pharmacist
Oral Treatments for Type 2 Diabetes Prescribing Support Pharmacist Learning Outcomes Familiar with classes of oral hypoglycaemic agents (OHAs) used in controlling blood glucose levels When to use each
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationInsulin Initiation, titration & Insulin switch in the Primary Care-KISS
Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Rotorua GP CME 9 June 2012 Dr Kingsley Nirmalaraj FRACP Endocrinologist, BOPDHB & Suite 9, Promed House, Tenth Ave, Tauranga Linda
More informationQuick Reference Guide
2018 Clinical Practice Guidelines Quick Reference Guide 416569-18 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Screening and Diagnosis Assess risk ANNUALLY if: Family history (First-degree
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationTreating the elderly patients with type 2 diabetes mellitus
Treating the elderly patients with type 2 diabetes mellitus Niki Katsiki MSc, PhD, MD, FRSPH IASO/EASO Scope Member EASD Diabetes & Cardiovascular Disease Group Member Member of the Executive Board of
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationJennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii
Individualized Diabetes Treatment for the Elderly Jennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii Extremely Relevant Baby Boomers are aging! ¼ of people age
More informationOral Treatments. SaminaAli Prescribing Support Pharmacist
Oral Treatments for Type 2 Diabetes SaminaAli Prescribing Support Pharmacist Learning Outcomes National Guidance Familiar with classes of oral hypoglycaemic agents (OHAs) used in controlling blood glucose
More informationSIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence
SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationCase study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease
Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease Authored by Paul Zimmet and Richard Nesto on behalf of the Global Partnership for Effective Diabetes Management.
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationJanice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT
Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT Objectives u At conclusion of the presentation the participant will: 1. Discuss challenges to glycemic control unique in the older population
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationDr A Pokrajac MD MSc MRCP Consultant
Dr A Pokrajac MD MSc MRCP Consultant Onset at 5-15 years of T1DM Can be present at diagnosis of T2DM Detect in regular MA/Cr screening (2X first urine sample, no UTI, no other causes) Contributing Factors
More information28-Aug-15. RACGP guidelines 2014/15. ADS guidelines Part 1 T2D Guidelines. Part 2 What comes after metformin?
Part 1 T2D Guidelines Oral therapies in T2 diabetes Dr Gary Kilov T2D Guidelines - What s New? What comes after metformin? 1 RACGP guidelines 2014/15 ADA-EASD: Anti-Hyperglycaemic therapy 2015 3 4 Inzucchi
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationDiagnosis and management of diabetes in older people
Diagnosis and management of diabetes in older people Anne Kilvert 1 MD, FRCP, Consultant Physician Charles Fox 1 BM, FRCP, Consultant Physician 1 Northampton General Hospital, Cliftonville, Northampton,
More informationSTEP 3: Add or Substitute with one of
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationPractical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
More informationMr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)
Dr David Kim Endocrinologist and General Physician Waitemata DHB and Apollo Specialist Clinic Albany Auckland Mr Rab Burtun Diabetes Nurse Specialist Waitemata DHB Waitakere Hospital Auckland 8:30-10:30
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationQuick Reference Guide
2018 Clinical Practice Guidelines Quick Reference Guide 416569-18 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Screening and diagnosis of type 2 diabetes in adults Assess risk factors for
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationArrange 3 Monthly Review Re-enforce LIFESTYLE advice and check DRUG COMPLIANCE at each visit Target HbA1c < 53mmol/mol
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationType-2 Diabetes The new Guideline NG28. Dr Martin Duerden
1 Type-2 Diabetes The new Guideline NG28 Dr Martin Duerden 2 Some Important Context Diagnosis Scale Outcomes 3 How is T2DM diagnosed? Once diabetes is diagnosed, the consequences for the individual are
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationDiabetes Management in New Brunswick Nursing Homes
Diabetes Management in New Brunswick Nursing Homes Prepared by Dr. Angela McGibbon March, 2016 As the population ages and with the rising incidence of diabetes, there are increasing numbers of people with
More informationPLEASE CHECK FULL SPECIFIC PRODUCT CHARACTERISTICS FOR MORE DETAILED AND CURRENT INFORMATION:
Metformin Standard tablets Modified-release tablets Metformin 1g sachets Metformin liquid 500mg/5ml (avoid use as expensive) < 2.00 5.32 for 56 tabs 500mg 13.16 for 60 sachets > 120 Ketoacidosis General
More informationOptimising prescribing in primary care in the face of multimorbidity and polypharmacy
University of Dundee School of Medicine Optimising prescribing in primary care in the face of multimorbidity and polypharmacy Bruce Guthrie Professor of Primary Care Medicine, University of Dundee NICE
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationDiabetes, Type 2 Management
CLINICAL GUIDELINE Diabetes, Type 2 Management A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. Clinical judgement should be exercised on the applicability
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationCoronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol)
CLINICAL GUIDELINE Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol) A guideline is intended to assist healthcare professionals in the choice of disease-specific
More informationRationalizing Medications. Tan Jianming Senior Pharmacist KTPH
Rationalizing Medications Tan Jianming Senior Pharmacist KTPH + Older patients are more likely to: 2 Have multiple co-morbid diseases Have age-related physiological changes that result in a reduced tolerance
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationThere have been important changes in diabetes care which may not be covered in undergraduate textbooks.
Diabetes Clinical update There have been important changes in diabetes care which may not be covered in undergraduate textbooks. Changes in the diagnosis of diabetes a) HbA1C Since 2011, World Health Organisation
More informationHypertension targets in the elderly. Sarah McCracken Consultant Geriatrician North Bristol NHS Trust September 2016
Hypertension targets in the elderly Sarah McCracken Consultant Geriatrician North Bristol NHS Trust September 2016 NICE (2011) Aim for a target clinic blood pressure below 150/90 mmhg in people aged 80
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationChallenges in type 2 diabetes control: slipping control and weight gain
control Earn 3 CPD Points online Case study Challenges in type 2 diabetes control: slipping control and weight gain Presenter Dr Sedeshan Govender Specialist Physician, Endocrinologist and Diabetologists
More informationDisclosures of Interest. Publications Diabetologia Key points to emphasize
Disclosures of Interest No conflicts or disclosures How to Use the American Diabetes Association s Type 2 Diabetes Treatment Algorithm Rashida Downing, MD, FAAFP Primary Care Physician JenCare Medical
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationDR HJ BODANSKY MD FRCP CONSULTANT PHYSICIAN LEEDS TEACHING HOSPITALS ASSOCIATE PROFESSOR, UNIVERSITY OF LEEDS
DR HJ BODANSKY MD FRCP CONSULTANT PHYSICIAN LEEDS TEACHING HOSPITALS ASSOCIATE PROFESSOR, UNIVERSITY OF LEEDS DIABETETES UPDATE 2015 AIMS OF THE SEMINAR Diagnosis Investigation Management When to refer
More informationThe New Hypertension Guidelines
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationFinding the sweet spot: Individualized targets for older adults with Type 2 DM
Finding the sweet spot: Individualized targets for older adults with Type 2 DM Samuel C. Durso, M.D., M.B.A. Mason F. Lord Professor of Medicine Director, Division of Geriatric Medicine and Gerontology
More informationInsulin Optimisation Workshop. Theingi Aung & Claire Rowell
Insulin Optimisation Workshop Theingi Aung & Claire Rowell Insulin initiation and titration Insulin Preparations Rapid-acting insulin analogues: onset of action of approximately 15 minutes and a duration
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 5 PURPOSE To assure that DOP inmates with Diabetes are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers are to follow these guidelines when treating
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationMedications for Type 2 Diabetes CDE Exam Preparation. Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy
Medications for Type 2 Diabetes CDE Exam Preparation Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy Competency for CDE Exam 3.1.A Oral Medications for Type 2 Diabetes
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationSIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION
SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION DR ROSE ZHAO-WEI TING ( 丁昭慧醫生 ) MBBS (HK), MRCP (UK), FHKCP, FHKAM (MEDICINE) Specialist in Endocrinology, Diabetes and Metabolism
More informationDIABETES AND RAMADAN FASTING
DIABETES AND RAMADAN FASTING Dr. A. Nigam, M.B.B.S., M.D. (Medicine) Specialist Internal Medicine Al Zahrawi Hospital, Ras Al Khaimah, U.A.E. It is estimated that UAE s population currently stands at approximately
More informationEnd of Life Diabetes Care
End of Life Diabetes Care Commissioned by Diabetes UK Supplementary Documents and Flowcharts Endorsed By: Diabetes Phases of End of Life and Medications A - Blue: All From Diagnosis Stable With Year Plus
More informationImplications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?
Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator
More information